Biotech Values

[Biowatch]

GENZ buys rights to Campath for MS from Bayer AG

GENZ buys "...commercialization rights to Bayer's cancer drug Campath and two other treatments in a deal potentially worth more than $1.25 billion over the next decade."

http://finance.yahoo.com/news/Genzyme-signs-drug-rights-apf-14796274.html

The PR:
http://finance.yahoo.com/news/Genzyme-and-Bayer-HealthCare-bw-14793826.html

I wonder if the recent news about a potential treatment for PML had an impact on the purchase decision?

"If PLEX and the malaria drug work against PML, this treatment may also be helpful to patients on at least four other drugs that have been linked to the brain infection, according to Naomi Aoki, a Biogen spokeswoman. Those include Roche’s Cellcept, used to prevent transplant rejections; Biogen and Genentech Inc.’s cancer drug Rituxan; Genentech’s psoriasis drug Raptiva, and Genzyme Corp.’s leukemia treatment Campath."
#msg-36535018